Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 1/20 | 0.39 |
| ▸ | GABRP | O00591 | 3/20 | 0.36 |
| ▸ | GABRD | O14764 | 3/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.36 |
| ▸ | GABRB1 | P18505 | 3/20 | 0.36 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.36 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.36 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.36 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.36 |
| ▸ | GABRA4 | P48169 | 3/20 | 0.36 |
| ▸ | GABRE | P78334 | 3/20 | 0.36 |
| ▸ | GABRA6 | Q16445 | 3/20 | 0.36 |
| ▸ | GABRG1 | Q8N1C3 | 3/20 | 0.36 |
| ▸ | GABRG3 | Q99928 | 3/20 | 0.36 |
| ▸ | GABRQ | Q9UN88 | 3/20 | 0.36 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16759894 | 1.00 | PDK1 (0.39) | PDK1GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL16963100 | 1.00 | PDK1 (0.39) | PDK1GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL30807499 | 0.85 | SIRT1 (0.35) | — | |
| SCHEMBL30807494 | 0.85 | SIRT1 (0.35) | — | |
| SCHEMBL17112648 | 0.74 | ATXN2 (0.35) | — | |
| SCHEMBL17112646 | 0.74 | ATXN2 (0.35) | — | |
| SCHEMBL17310817 | 0.74 | CHRNA4 (0.51) | — | |
| Hydrochloric Acid SCHEMBL17310834 | 0.73 | CHRNA4 (0.50) | — | |
| SCHEMBL17112561 | 0.73 | CHRNB2 (0.37) | — | |
| SCHEMBL18315515 | 0.73 | ENPP2 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4704830-A2 | MRGPRX2 INHIBITORS AND METHODS OF USE THEREOF | Septerna, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| WO-2024226914-A2 | MRGPRX2 ANTAGONISTS AND METHODS OF USE THEREOF | SEPTERNA, INC. (US) | 2024-10-31 | — | — | WO | disclosed |
| WO-2024043741-A1 | AUTOTAXIN INHIBITOR COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | 주식회사 레고켐 바이오사이언스 | 2024-02-29 | — | — | WO | disclosed |
| EP-3590940-B1 | HEXAHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES AND RELATED COMPOUNDS AS AUTOTAXIN (ATX) INHIBITORS AND AS INHIBITORS OF THE LYSOPHOSPHATIDIC ACID (LPA) PRODUCTION FOR TREATING E.G. RENAL DISEASES | HOFFMANN LA ROCHE (CH) | 2021-06-09 | — | — | EP | disclosed |
| CN-107922412-B | Bicyclic compounds as ATX inhibitors | 豪夫迈·罗氏有限公司 | 2021-02-23 | — | — | CN | disclosed |
| US-20210015792-A1 | OCTAHYDRO-CYCLOBUTA[1,2-c;3,4-c']DIPYRROL-2-YL | HOFFMANN-LA ROCHE INC. (US) | 2021-01-21 | — | — | US | disclosed |
| US-10849881-B2 | Octahydro-cyclobuta[1,2-c;3,4-c′]dipyrrol-2-yl | HOFFMANN-LA ROCHE INC. (US) | 2020-12-01 | — | — | US | disclosed |
| US-20200339570-A1 | BICYCLIC DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2020-10-29 | — | — | US | disclosed |
| US-10800786-B2 | Bicyclic compounds as ATX inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2020-10-13 | — | — | US | disclosed |
| US-20200216457-A1 | BICYCLIC COMPOUNDS AS AUTOTAXIN (ATX) AND LYSOPHOSPHATIDIC ACID (LPA) PRODUCTION INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2020-07-09 | — | — | US | disclosed |
| US-20170008900-A1 | BICYCLIC COMPOUNDS AS AUTOTAXIN (ATX) AND LYSOPHOSPHATIDIC ACID (LPA) PRODUCTION INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2017-01-12 | — | — | US | disclosed |
| EP-2861566-B1 | NEW DIAZASPIROCYCLOALKANE AND AZASPIROCYCLOALKANE | HOFFMANN LA ROCHE (CH) | 2016-12-21 | — | — | EP | disclosed |
| US-9493486-B2 | Diazaspirocycloalkane and azaspirocycloalkane | HOFFMANN-LA ROCHES INC. (US) | 2016-11-15 | — | — | US | disclosed |
| EP-3074400-A1 | NEW OCTAHYDRO-CYCLOBUTA [1,2-c;3,4-c']DIPYRROL-2-YL | F. Hoffmann-La Roche AG (CH) | 2016-10-05 | — | — | EP | disclosed |
| US-20160264586-A1 | OCTAHYDRO-CYCLOBUTA [1,2-c;3,4-c']DIPYRROL-2-YL | HOFFMANN-LA ROCHE INC. (US) | 2016-09-15 | — | — | US | disclosed |
| US-20150353559-A1 | NEW BICYCLIC DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2015-12-10 | — | — | US | disclosed |
| WO-2015144605-A1 | BICYCLIC COMPOUNDS AS AUTOTAXIN (ATX) AND LYSOPHOSPHATIDIC ACID (LPA) PRODUCTION INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-10-01 | — | — | WO | disclosed |
| EP-2900669-A1 | NEW BICYCLIC DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2015-08-05 | — | — | EP | disclosed |
| WO-2015078803-A1 | NEW OCTAHYDRO-CYCLOBUTA [1,2-c;3,4-c']DIPYRROL-2-YL | F. HOFFMANN-LA ROCHE AG (CH) | 2015-06-04 | — | — | WO | disclosed |
| US-20150099734-A1 | NEW DIAZASPIROCYCLOALKANE AND AZASPIROCYCLOALKANE | HOFFMANN-LA ROCHE INC. (US) | 2015-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10800786-B2 | Bicyclic compounds as ATX inhibitors | ATXN2, ATXN2L, ATXN10 | PDK1 4570/4885GABRP 2827/4885GABRD 3896/4885 |
| US-20170008900-A1 | BICYCLIC COMPOUNDS AS AUTOTAXIN (ATX) AND LYSOPHOSPHATIDIC ACID (LPA) PRODUCTION INHIBITORS | ENPP2, LPAR1, LPAR2 | PDK1 4163/4885GABRP 2407/4885GABRD 4248/4885 |
| US-20200216457-A1 | BICYCLIC COMPOUNDS AS AUTOTAXIN (ATX) AND LYSOPHOSPHATIDIC ACID (LPA) PRODUCTION INHIBITORS | ENPP2, LPAR1, LPAR2 | PDK1 4163/4885GABRP 2407/4885GABRD 4248/4885 |
| US-20160264586-A1 | OCTAHYDRO-CYCLOBUTA [1,2-c;3,4-c']DIPYRROL-2-YL | NPY1R, NPY2R, DECR1 | PDK1 525/4885GABRP 2403/4885GABRD 2203/4885 |
| US-20150353559-A1 | NEW BICYCLIC DERIVATIVES | BICRA, CCNY, UQCRB | PDK1 1443/4885GABRP 1245/4885GABRD 2370/4885 |
| US-20200339570-A1 | BICYCLIC DERIVATIVES | CCNY, BICRA, UQCRB | PDK1 1913/4885GABRP 1284/4885GABRD 2567/4885 |
| US-20150099734-A1 | NEW DIAZASPIROCYCLOALKANE AND AZASPIROCYCLOALKANE | DAPK2, DAPK1, IDH3A | PDK1 249/4885GABRP 1354/4885GABRD 1259/4885 |
| US-20210015792-A1 | OCTAHYDRO-CYCLOBUTA[1,2-c;3,4-c']DIPYRROL-2-YL | NPY1R, NPY2R, DECR1 | PDK1 525/4885GABRP 2403/4885GABRD 2203/4885 |
| US-10849881-B2 | Octahydro-cyclobuta[1,2-c;3,4-c′]dipyrrol-2-yl | NPY1R, NPY2R, DECR1 | PDK1 513/4885GABRP 2535/4885GABRD 2298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.